Table 3 Interaction of ABT-737 (0.5 µM) with doxorubicin (1.0 µM a), gemcitbine (0.5 µM b) or cisplatin (5.0 µM c) in five thyroid carcinoma cell lines
(a) Cell line | ABT-737 | Doxorubicin | ABT-737 + doxorubicin | CI |
|---|---|---|---|---|
FTC236 (FTC)) | 96.2 ± 6.5 | 92.4 ± 4.2 | 68.4 ± 5.9 | 1.30 syn. |
ML1 (FTC) | 86.5 ± 7.3 | 75.9 ± 5.4 | 37.6 ± 1.5 | 1.75 syn. |
BHT101 (PTC) | 84.4 ± 5.5 | 90.1 ± 6.1 | 78.6 ± 6.7 | 0.97 add. |
SW1736 (ATC) | 95.6 ± 7.0 | 74.3 ± 4.8 | 34.7 ± 3.0 | 2.05 syn. |
HTh7 (ATC) | 98.6 ± 4.6 | 65.0 ± 5.5 | 62.2 ± 3.1 | 1.03 add. |
(b) Cell line | ABT-737 | Gemcitabine | ABT-737 + gemcitabine | CI |
|---|---|---|---|---|
FTC236 (FTC) | 99.1 ± 4.8 | 79.4 ± 4.8 | 61.3 ± 5.0 | 1.28 syn. |
ML1 (FTC) | 86.0 ± 5.3 | 83.2 ± 5.4 | 54.8 ± 3.8 | 1.31 syn. |
BHT101 (PTC) | 84.9 ± 6.9 | 87.6 ± 6.7 | 76.2 ± 5.2 | 0.98 add. |
SW1736 (ATC) | 96.8 ± 6.1 | 78.5 ± 3.8 | 56.1 ± 2.5 | 1.35 syn. |
HTh7 (ATC) | 97.3 ± 7.5 | 71.8 ± 4.2 | 42.9 ± 3.9 | 1.63 syn. |
(c) Cell line | ABT-737 | Cisplatin | ABT-737 + cisplatin | CI |
|---|---|---|---|---|
FTC236 (FTC) | 95.9 ± 7.9 | 102.6 ± 9.3 | 99.7 ± 7.4 | 0.99 add. |
ML1 (FTC) | 84.8 ± 5.8 | 97.3 ± 7.4 | 83.5 ± 6.9 | 0.99 add. |
BHT101 (PTC) | 83.4 ± 6.3 | 98.1 ± 8.7 | 81.7 ± 5.7 | 1.00 add. |
SW1736 (ATC) | 95.0 ± 5.6 | 103.8 ± 7.2 | 101.9 ± 6.9 | 0.97 add. |
HTh7 (ATC) | 99.3 ± 7.8 | 98.5 ± 5.9 | 100.2 ± 7.0 | 0.98 add. |